Search

Your search keyword '"Cruz, C. Russell"' showing total 23 results
Start Over Author "Cruz, C. Russell"
23 results on '"Cruz, C. Russell"'

3. Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT

Author

Kinoshita, Hannah, Cooke, Kenneth R., Grant, Melanie, Stanojevic, Maja, Cruz, C. Russell, Keller, Michael, Fortiz, Maria Fernanda, Hoq, Fahmida, Lang, Haili, Barrett, A. John, Liang, Hua, Tanna, Jay, Zhang, Nan, Shibli, Abeer, Datar, Anushree, Fulton, Kenneth, Kukadiya, Divyesh, Zhang, Anqing, Williams, Kirsten M., Dave, Hema, Dome, Jeffrey S., Jacobsohn, David, Hanley, Patrick J., Jones, Richard J., and Bollard, Catherine M.

Published
2022
Full Text
View/download PDF

4. SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein

Author

Keller, Michael D., Harris, Katherine M., Jensen-Wachspress, Mariah A., Kankate, Vaishnavi V., Lang, Haili, Lazarski, Christopher A., Durkee-Shock, Jessica, Lee, Ping-Hsien, Chaudhry, Kajal, Webber, Kathleen, Datar, Anushree, Terpilowski, Madeline, Reynolds, Emily K., Stevenson, Eva M., Val, Stephanie, Shancer, Zoe, Zhang, Nan, Ulrey, Robert, Ekanem, Uduak, Stanojevic, Maja, Geiger, Ashley, Liang, Hua, Hoq, Fahmida, Abraham, Allistair A., Hanley, Patrick J., Cruz, C. Russell, Ferrer, Kathleen, Dropulic, Lesia, Gangler, Krista, Burbelo, Peter D., Jones, R. Brad, Cohen, Jeffrey I., and Bollard, Catherine M.

Published
2020
Full Text
View/download PDF

10. EPCT-24 THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS

Author

Grant, Melanie, primary, Fortiz, Maria, additional, Wang, Lu, additional, Lang, Haili, additional, Datar, Anushree, additional, Reynolds, Emily, additional, Terpilowski, Madeleine, additional, Geiger, Ashley, additional, Lazarski, Chris, additional, Tanna, Jay, additional, Pitino, Adriana, additional, Zhang, Nan, additional, Hoq, Fahmida, additional, Hanley, Patrick, additional, Cruz, C Russell, additional, Kilburn, Lindsay, additional, Packer, Roger, additional, Rood, Brian, additional, and Bollard, Catherine, additional

Published
2021
Full Text
View/download PDF

11. Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study

Author

Hont, Amy B., primary, Cruz, C. Russell, additional, Ulrey, Robert, additional, O’Brien, Barbara, additional, Stanojevic, Maja, additional, Datar, Anushree, additional, Albihani, Shuroug, additional, Saunders, Devin, additional, Hanajiri, Ryo, additional, Panchapakesan, Karuna, additional, Darko, Sam, additional, Banerjee, Payal, additional, Fortiz, Maria Fernanda, additional, Hoq, Fahmida, additional, Lang, Haili, additional, Wang, Yunfei, additional, Hanley, Patrick J., additional, Dome, Jeffrey S., additional, Bollard, Catherine M., additional, and Meany, Holly J., additional

Published
2019
Full Text
View/download PDF

13. Ex vivo expanded multi-antigen specific lymphocytes for the treatment of solid tumors.

Author

Houghtelin, Amy, primary, Cruz, C. Russell, additional, Ulrey, Robert, additional, O'Brien, Barbara, additional, Stanojevic, Maja, additional, Albihaini, Shuroug, additional, Saunders, Devin, additional, Hoq, Fahmida, additional, Fortiz, Maria Fernanda, additional, Lang, Haili, additional, Hanley, Patrick, additional, Bollard, Catherine, additional, and Meany, Holly Jane, additional

Published
2018
Full Text
View/download PDF

15. Editorial

Author

Cruz, C. Russell Y., primary, Andreeff, Michael, additional, and Barrett, John, additional

Published
2016
Full Text
View/download PDF

16. 75. Development of an LMP-Specific T Cell Bank for Third Party Use as a Curative Strategy Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant

Author

McLaughlin, Lauren, primary, Roesch, Lauren, additional, Mintz, E. Kathy, additional, McCormick, Sarah, additional, Barese, Cecilia, additional, Williams, Elizabeth, additional, Joshi, Neha, additional, Hoq, Fahmida, additional, Keller, Michael, additional, Cruz, C. Russell, additional, Cairo, Mitchell S., additional, Hochberg, Jessica, additional, Hanley, Patrick J., additional, and Bollard, Catherine M., additional

Published
2016
Full Text
View/download PDF

20. CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo

Author

Hanley, Patrick J., primary, Melenhorst, Jan J., additional, Nikiforow, Sarah, additional, Scheinberg, Phillip, additional, Blaney, James W., additional, Demmler-Harrison, Gail, additional, Cruz, C. Russell, additional, Lam, Sharon, additional, Krance, Robert A., additional, Leung, Kathryn S., additional, Martinez, Caridad A., additional, Liu, Hao, additional, Douek, Daniel C., additional, Heslop, Helen E., additional, Rooney, Cliona M., additional, Shpall, Elizabeth J., additional, Barrett, A. John, additional, Rodgers, John R., additional, and Bollard, Catherine M., additional

Published
2015
Full Text
View/download PDF

21. HIV-Specific, Ex VivoExpanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals

Author

Sung, Julia A., Patel, Shabnum, Clohosey, Matthew L., Roesch, Lauren, Tripic, Tamara, Kuruc, JoAnn D., Archin, Nancie, Hanley, Patrick J., Cruz, C. Russell, Goonetilleke, Nilu, Eron, Joseph J., Rooney, Clio M., Gay, Cynthia L., Bollard, Catherine M., and Margolis, David M.

Abstract

Adoptive T cell therapy has had dramatic successes in the treatment of virus-related malignancies and infections following hematopoietic stem cell transplantation. We adapted this method to produce ex vivoexpanded HIV-specific T cells (HXTCs), with the long-term goal of using HXTCs as part of strategies to clear persistent HIV infection. In this phase 1 proof-of-concept study (NCT02208167), we administered HXTCs to antiretroviral therapy (ART)-suppressed, HIV-infected participants. Participants received two infusions of 2 × 107cells/m2HXTCs at a 2-week interval. Leukapheresis was performed at baseline and 12 weeks post-infusion to measure the frequency of resting cell infection by the quantitative viral outgrowth assay (QVOA). Overall, participants tolerated HXTCs, with only grade 1 adverse events (AEs) related to HXTCs. Two of six participants exhibited a detectable increase in CD8 T cell-mediated antiviral activity following the two infusions in some, but not all, assays. As expected, however, in the absence of a latency reversing agent, no meaningful decline in the frequency of resting CD4 T cell infection was detected. HXTC therapy in ART-suppressed, HIV-infected individuals appears safe and well tolerated, without any clinical signs of immune activation, likely due to the low residual HIV antigen burden present during ART.

Published
2018
Full Text
View/download PDF

22. Limited Immunogenicity of an HLA-A*03:01-restricted Epitope of Erv-k-env in Non-hiv-1 Settings: Implications for Adoptive Cell Therapy in Cancer.

Author

Grundy EE, Shaw LC, Wang L, Powell DJ, Ostrowski M, Jones RB, Cruz CRY, Gordish-Dressman H, Bollard CM, and Chiappinelli KB

Abstract

Repetitive elements (REs) are often expressed at higher levels in tumor cells than normal cells, implicating these genomic regions as an untapped pool of tumor-associated antigens. In ovarian cancer (OC), protein from the RE ERV-K is frequently expressed by tumor cells. Here we determined whether the targeting of a previously identified immunogenic epitope in the envelope gene (env) of ERV-K resulted in target antigen specificity in non-HIV-1 settings. We found that transducing healthy donor T cells with an ERV-K-Env-specific T cell receptor construct resulted in antigen specificity only when co-cultured with HLA-A*03:01 B lymphoblastoid cells. Furthermore, these transduced T cells were not specific for HLA-A*03:01 + OC cells nor for the cognate peptide in HLA-matched systems from multiple healthy donors. These data suggest that the ERV-K-Env epitope recognized by this T cell receptor is of low immunogenicity and has limited potential as a T cell target for OC., Competing Interests: Additional Declarations: Competing interest reported. Erin E. Grundy: no such conflicts exist Lauren C. Shaw: no such conflicts exist Daniel J. Powell Jr.: no such conflicts exist Mario Ostrowski: no such conflicts exist R. Brad Jones: no such conflicts exist C. Russell Y. Cruz: no such conflicts exist Heather Gordish-Dressman: no such conflicts exist Catherine M. Bollard: no such conflicts exist Katherine B. Chiappinelli: consultant for Rome Therapeutics DISCLOSURES & COMPETING INTERESTS KBC is a consultant for Rome Therapeutics.

Published
2024
Full Text
View/download PDF

23. T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.

Author

Cruz CR and Bollard CM

Subjects
Animals, Hematologic Neoplasms diagnosis, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Graft vs Leukemia Effect immunology, Hematologic Neoplasms immunology, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation methods, Killer Cells, Natural immunology, T-Lymphocytes immunology
Abstract

Hematopoietic stem cell transplantation has revolutionized the treatment of hematologic malignancies, but infection, graft-versus-host disease and relapse are still important problems. Calcineurin inhibitors, T-cell depletion strategies, and immunomodulators have helped to prevent graft-versus-host disease, but have a negative impact on the graft-versus-leukemia effect. T cells and natural killer cells are both thought to be important in the graft-versus-leukemia effect, and both cell types are amenable to ex vivo manipulation and clinical manufacture, making them versatile immunotherapeutics. We provide an overview of these immunotherapeutic strategies following hematopoietic stem cell transplantation, with discussions centered on natural killer and T-cell biology. We discuss the contributions of each cell type to graft-versus-leukemia effects, as well as the current research directions in the field as related to adoptive cell therapy after hematopoietic stem cell transplantation., (Copyright© Ferrata Storti Foundation.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results